FOX's Special Committee Issues Update On Review Of Potential Transaction

Fox Corp. (FOX,FOXA) said the Special Committee of the Board is in the process of thoroughly reviewing a potential combination with News Corp. It has retained independent advisors consisting of J.P. Morgan as its financial advisor and Wachtell, Lipton, Rosen & Katz as its legal advisor. The company noted that the Committee has made no determination with respect to a combination at this stage.

The Special Committee is composed solely of independent directors not affiliated with the Murdoch family - Jacques Nasser, Roland Hernandez, Anne Dias, Paul Ryan, and William Burck, with Nasser, Fox Corp.'s Lead Independent Director, serving as chair.

The letters from Rupert Murdoch and the Murdoch Family Trust indicated that they will not vote in favor of a transaction unless it is both recommended by the special committee and approved by a majority vote of the shares held by non-affiliated stockholders entitled to vote.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT